A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1

Authors :: Roestenberg, Meta
Walk, Jona
van der Boor, Saskia C.
Langenberg, Marijke C. C.
Hoogerwerf, Marie-Astrid
Janse, Jacqueline J.
Manurung, Mikhael
Yap, X. Zen
García, Amanda Fabra
Koopman, Jan Pieter R.
Meij, Pauline
Wessels, Els
Teelen, Karina
van Waardenburg, Youri M.
van de Vegte-Bolmer, Marga
van Gemert, Geert Jan
Visser, Leo G.
van der Ven, André J. A. M.
de Mast, Quirijn
Natasha, K. C.
Abebe, Yonas
Murshedkar, Tooba
Billingsley, Peter F.
Richie, Tom L.
Sim, B. Kim Lee
Janse, Chris J.
Hoffman, Stephen L.
Khan, Shahid M.
Sauerwein, Robert W.
Source :: Science Translational Medicine; May 2020, Vol. 12 Issue: 544
Publication Year :: 2020
Abstract: The genetically attenuated malaria vaccine PfSPZ-GA1 is safe, immunogenic, and has suboptimal protective efficacy in people.

Full Text Access

Tools